• Journal Article

Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity

Citation

Javitt, J. C., Zlateva, G. P., Earnshaw, S., Pleil, A. M., Graham, C., Brogan, A., ... Adamis, A. R. (2008). Cost-effectiveness model for neovascular age-related macular degeneration: Comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health, 11(4), 563-574.

Abstract